|
Regence medical policies are evidence-based and take
into account the available scientific evidence published
in peer-reviewed journals, as well as evidence-based
clinical practice guidelines and specialty society
statements. The process for Regence medical policy
development is described in the Introduction to the
Regence Medical Policy Manual.
In addition, Regence values the experience and opinions
of practicing physicians and other health care providers.
Your feedback on our policies is welcome and is an
important part of our annual policy review process.
You may provide feedback to us on the following policies
by:
- Responding to the email that directed
you to this page. Please be sure to identify
the policy you are providing comments on in your
email response.
- Accessing our contact page: Contact
Medical Policy Staff. Please be sure to identify
the policy in the policy name field, as well as
your name, specialty and contact information. (Note:
contact information only needs to be included if
you do not regularly receive medical policy email
notification from Regence.)
POLICIES
SCHEDULED FOR REVIEW, LISTED BY
SPECIALTY:
|
Endocrinology - (1)
|
Genetics - (2)
|
Hematology Oncology - (7)
|
Neurosurgery - (1)
|
Oncology - (12)
- Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening, Genetic Testing 12
- Intensity Modulated Radiation Therapy (IMRT) of the Thorax (Breast, Esophageal, and Lung Cancer and Malignant Pleural Mesothelioma), Medicine 136
- Intensity Modulated Radiation Therapy (IMRT) of the Prostate, Medicine 137
- Intensity Modulated Radiation Therapy (IMRT) of the Head and Neck Cancers and Thyroid Cancer, Medicine 138
- Intensity Modulated Radiation Therapy (IMRT) of the Abdomen and Pelivs, Medicine 139
- Intensity Modulated Radiation Therapy (IMRT): Entral Nervous System (CNS) and Vertebral Tumors, Medicine 147
- Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant, Transplant 45.03
- Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms, Transplant 45.24
- Hematopoietic Stem-Cell Transplantation for Chronic Myelogenous Leukemia, Transplant 45.31
- Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma, Transplant 45.33
- Hematopoietic Stem-Cell Transplantation for Solid Tumors of Childhood, Transplant 45.37
- Hematopoietic Stem-Cell Transplantation in the Treatment of Germ-Cell Tumors, Transplant 45.38
|
Orthopedics - (1)
|
Podiatry - (1)
|
Primary Care/Internal
Medicine -
(2)
|
Radiation Oncology - (5)
|
Radiology - (1)
|
Solid Organ Transplants - (1)
|
Urology - (1)
|
|
